Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pralsetinib · Gavreto, BLU-123244

Small molecule · Inhibitor of RET proto-oncogene (RET) · developed by Rigel Pharms

Approved FDA, Sep 2020
RIGL Developer
1 Registered trials

What is Pralsetinib?

Pralsetinib is an oral kinase inhibitor that potently blocks wild-type RET and oncogenic RET fusions and mutations, suppressing the signaling that drives uncontrolled tumor cell proliferation. It also inhibits several other kinases at higher concentrations. It is studied in non-small cell lung cancer, thyroid cancer, and solid tumor malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Gavreto, BLU-123244, BLU-667
Drug type
Small molecule
Targets
RET proto-oncogene (RET), DDR1 (secondary target), TRKC (NTRK3) (NTRK3) (secondary target), FLT3 (secondary target), JAK1 (secondary target), JAK2 (secondary target)
Mechanism
Inhibitor of RET proto-oncogene (RET)
Pathways
RET downstream signaling leading to uncontrolled cell proliferation
Therapy area
Oncology
Developer
Rigel Pharms (RIGL)
FDA status
Approved as Gavreto (September 4, 2020), NDA213721 · FDA label
UNII
1WPE73O1WV

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 30, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07704658 Phase 4 NSCLC (Non-small Cell Lung Cancer) Recruiting RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced MalignanciesNSCLC (Non-small Cell Lung Cancer)Solid Tumor MalignanciesThyroid Cancer

Other drugs acting on RET

More from Rigel Pharms

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.

Follow RIGL, the company behind Pralsetinib

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.